Capecitabine Accord 150 mg film-coated tablets
Sponsors
Fondation Franc.Cancerologie Digestive, Astrazeneca AB, Institut Gustave Roussy, Bristol-Myers Squibb Services Unlimited Company, Exscientia AI Limited
Conditions
Adult patients with intermediate low or mid rectal adenocarcinoma to be treated with total neoadjuvant therapy (TNT) potentially eligible for rectal preservation.Advanced solid tumorsAmpullary adenocarcinomaBiliary tract carcinomaColorectal Cancer and Breast CancerColorectal liver metastasesLocally Advanced Unresectable Esophageal Squamous Cell CarcinomaLocally advanced colon cancer (LACC)
Phase 1
A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors
RecruitingCTIS2023-508227-13-00
Start: 2023-06-19Target: 112Updated: 2026-01-14
A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)
Active, not recruitingCTIS2023-505690-33-00
Start: 2022-03-11Target: 12Updated: 2026-01-21
A Phase 1a/1b Study of ELVN-002 Combined with Trastuzumab in Advanced Stage HER2+ Solid tumors, and ELVN-002 Combined with Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
Active, not recruitingCTIS2023-509716-29-00
Start: 2024-09-23Target: 156Updated: 2025-11-24
Phase 2
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carcinoma. A non-comparative randomized phase II study
CompletedCTIS2023-503807-27-00
End: 2023-08-29Target: 219Updated: 2023-07-07
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Start: 2020-05-05Target: 307Updated: 2026-01-19
A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 or Stage III MMRp/ MSS colon cancer
RecruitingCTIS2024-513441-36-00
Start: 2024-11-27Target: 170Updated: 2025-12-18
ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER.
Not yet recruitingCTIS2024-519825-39-00
Target: 238Updated: 2025-01-30
Phase 3
Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenocarcinoma (TRESOR)
RecruitingCTIS2023-506885-30-00
Start: 2024-03-26Target: 212Updated: 2025-03-11
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN).
Active, not recruitingCTIS2023-506413-22-00
Start: 2021-03-31Target: 48Updated: 2026-01-09
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.
RecruitingCTIS2024-511070-68-01
Start: 2024-09-24Target: 294Updated: 2025-08-29
COLLISION RELAPSE trial
Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvant systemic therapy, a phase III prospective randomized controlled trial
Not yet recruitingCTIS2024-515341-41-01
Target: 360Updated: 2024-12-11
PembroLizumab Adjuvant in patients with early-stage Triple NEgaTive breast cancer with residual disease after neoadjuvant pembrolizumab plus chemotherapy – the multicenter, randomized phase III, pragmatic PLANET trial
Not yet recruitingCTIS2025-524229-41-00
Target: 1000Updated: 2026-04-01